JosephHabibi_MD Profile Banner
Joseph Sleiman, MD, FACP Profile
Joseph Sleiman, MD, FACP

@JosephHabibi_MD

Followers
5K
Following
13K
Media
1K
Statuses
5K

🏳️‍🌈🇱🇧 IBD fellow @ClevelandClinic, Alumni @PittGILiverNutr #SoMe Editor @ACG_EBGI ➡️ @AGA_CGH🧵 #CGH4ALL #IBDAlgorithm @MondayNightIBD👨‍⚕️ tweets my own

Cleveland, OH
Joined November 2012
Don't wanna be here? Send us removal request.
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
11 days
Happy to bring back my USA education & GI experience in a full circle . 📣 Virtual Talk w/ Real-world advice:.-Residency & fellowship matching.-Research & leadership as an IMG.-Career-building in IM & GI. 🎯My journey from medical school in Lebanon to training & securing a
Tweet media one
0
13
77
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
7 days
Tweet media one
0
5
9
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
8 days
#CGH4ALL 📣.💊 GLP-1 agonists in IBD?.👀 Safe, effective for weight loss.🔥 May help reduce inflammation (↓ CRP).🌟 Especially promising in ulcerative colitis!. Read the complete study here @AGA_CGH . 🔗 Reported by @arianapg. @phillyIBDdoc @blakely_md
Tweet media one
1
8
30
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
9 days
#CGH4ALL @AGA_CGH 📣. With rising prevalence of chronic liver disease in young adults, there is an increase in relevance for data on safety and outcomes for infertility treatment!. Reported by @Ansari_Zaid7. 🔗 @Meera_Garriga @MonikaSarkar @whcop
Tweet media one
0
7
10
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
10 days
#CGH4ALL📣 💥.Injectable Naltrexone has an overall better GI and liver safety profile compared to other FDA-approved drugs for Alcohol use disorder (AUD) . @Wei_Zhang_Liver @doc_sooyoung. @AGA_CGH🔥!🔗 . Reported by @ifrahfatima. @BlaneyMD @NoureddinMD
Tweet media one
0
8
24
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
12 days
RT @jalpa_devi: 😄 2 out of 2 abstracts accepted, excited to present at #ACG2025 in Phoenix🌵!.🧠 P1110: Global HCP Perspectives on AI in IBD….
0
4
0
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
13 days
3rd @Y_ECCO_IBD Mentorship Forum, Vienna, Austria. ✅Becoming an IKL (Innovation knowledge Leader), not just a KOL.☑️Succeeding at living as a physician & scientist.✅Multi-center trial design simulation + shark tank.☑️New & old friends. @ibdseb @bverstockt @virgisolitano
Tweet media one
Tweet media two
Tweet media three
Tweet media four
0
4
30
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
13 days
#CGH4ALL 📣.🧐How risky are subcentimeter liver nodules?.📊This systematic review shows up to 20% may develop HCC, but newer studies show lower risk.🎯Better risk stratification models are needed!. 🖇️ Reported by @arianapg. @KarimDahanMD @darinedaher
Tweet media one
0
0
10
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
14 days
RT @SuhaAbushamma: 🗞️Check out the #REACHIBD summer newsletter for #GI fellows and early-career #IBD pros. Insightful patient stories, ☀️ #….
0
10
0
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
14 days
RT @ign76: 🔵 Interested in Global IBD and future scenarios?. Very happy to see our review published in @UEGJournal with IBD Master and good….
0
20
0
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
14 days
#CGH4ALL @AGA_CGH 📣. As we look for more targets in therapy of UC, this study reports on an IL-22 Agonist that did not have efficacy when compared to placebo or Vedo!. 🔗 Reported by @Ansari_Zaid7. @ibd_pal @EdBarnesMD @IBDGastroDocSg @Bealoquebea
Tweet media one
0
9
23
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
15 days
#CGH4ALL @AGA_CGH 📣. It is inevitable that you will see patients with disorders of gut-brain interaction– read this expert review to learn about evaluation for coexisting hypermobility, orthostasis and mast cell disorders!. Reported by @Ansari_Zaid7. 🔗
Tweet media one
0
2
13
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
16 days
#CGH4ALL📣 💥.🚨 New international consensus on ASUC trial design!.📖 #IBD #ASUC #UlcerativeColitis #ClinicalTrials #Gastroenterology. @AGA_CGH🔥!🔗 Reported by @ifrahfatima
Tweet media one
1
6
23
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
17 days
#CGH4ALL 📣 @AGA_CGH.💊 Do antibiotics fuel early-onset colon cancer?.🧪 In this large US study, the answer is: not likely.📉 No clear link found between adult antibiotic use and EOCRC risk. 🖇️ Reported by @arianapg. @JeffLeeMD @aileenbui @kpnorcalGI
Tweet media one
1
3
14
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
20 days
RT @AliSoroushMD: 🚨 Application deadline extended to July 18! . The ASGE AI Scholars Program offers a fully funded year of AI training for….
aiforgi.org
Advance your career in gastroenterology with ASGE's AI Scholar Program—an innovative initiative training future leaders in artificial intelligence applications for GI care.
0
5
0
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
21 days
RT @AGA_CGH: 📢 CGH is thrilled to welcome its new Editorial Fellows @slchung_md and @SedkiMD. 📰 To see the editorial fellows selected for….
0
1
0
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
23 days
RT @AGA_CGH: Endoscopic Sedation Type During FLIP Panometry Does Not Significantly Impact FLIP Motility Classification Relative to Manometr….
0
3
0
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
26 days
RT @clivejmiranda: ✨ My 1️⃣st year of GI fellowship was littered with pearls of wisdom. Here are a few of them:. 🕕 Ideally get it to 6 o’cl….
0
21
0
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
27 days
#CGH4ALL 📣. #ImmuneCheckpointInhibitor–Induced Type 1 Diabetes.🔍 Rare but serious irAE - early recognition is key!. 📰 @AGA_CGH.🌐 Reported by @KAlsabb. @MaisamHaijaMD @VinayChandraMD @FergaGleeson @Vkumbhari @ChahalPrabhleen @DrJohnKisiel
Tweet media one
0
5
17
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
28 days
#CGH4ALL.Which comorbidities😷 may impact the health-related quality of life🏃‍♂️in patients with alcohol related liver disease💉?. @AGA_CGH .🔗 @ebtapper @JasmohanBajaj @JonathanStineMD @AniKardashianMD @lilydaramd @KathleenCoreyMD @AdamMikMD @VivianOrtizMD
Tweet media one
0
4
10